Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update

Ascendis Pharma A/S (NASDAQ:ASND) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 3,410,000 shares, a growth of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily trading volume, of 634,100 shares, the short-interest ratio is presently 5.4 days.

Analyst Upgrades and Downgrades

ASND has been the topic of a number of analyst reports. Oppenheimer cut their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday. JPMorgan Chase & Co. reduced their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI upped their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $126.51 on Friday. The firm has a 50-day simple moving average of $132.30 and a two-hundred day simple moving average of $132.66. The stock has a market cap of $7.67 billion, a PE ratio of -13.59 and a beta of 0.66. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the business. Groupama Asset Managment purchased a new position in Ascendis Pharma A/S in the third quarter valued at $60,000. Signaturefd LLC grew its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares in the last quarter. Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S during the second quarter worth approximately $205,000. Finally, Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.